CFRI TOP 5 "READ MORE"
Links to our 5 latest full featured articles.
KINNEAR PHARMACEUTICALS TO RECEIVE UP TO $3M TO FOR DEVELOPMENT OF ANTI-INFECTIVE FROM CF FOUNDATION
KINNEAR PHARMACEUTICALS TO RECEIVE UP TO $3M TO FOR DEVELOPMENT OF ANTI-INFECTIVE FROM CF FOUNDATION
FDA TO REVIEW TRIKAFTA FOR PATIENTS AS YOUNG AS SIX YEARS
FDA TO REVIEW TRIKAFTA FOR PATIENTS AS YOUNG AS SIX YEARS
AzurRx STARTS DOSING FIRST CF PATIENTS IN STUDY OF LIPASE ENZYME MS1819
AzurRx STARTS DOSING FIRST CF PATIENTS IN STUDY OF LIPASE ENZYME MS1819
MINORITIES IN US OFTEN INELIGIBLE FOR CFTR MODULATORS DUE TO POORLY STUDIED MUTATIONS
MINORITIES IN US OFTEN INELIGIBLE FOR CFTR MODULATORS DUE TO POORLY STUDIED MUTATIONS
UPDATE: WASHINGTON STATE SENATE HEALTH AND LONG TERM CARE COMMITTEE HEARS TESTIMONY ON SB 5020: "Rx DRUG PRICE INCREASES"
UPDATE: WASHINGTON STATE SENATE HEALTH AND LONG TERM CARE COMMITTEE HEARS TESTIMONY ON SB 5020: "Rx DRUG PRICE INCREASES"